Application of compound Chinese patent medicine for treating COVID-19

Abstract

The invention discloses application of a compound Chinese patent medicine for treating COVID-19. The compound Chinese patent medicine is prepared from radix scrophulariae, fructus gardeniae, rhizoma coptidis, fructus forsythia, herba artemisiae scopariae, poria cocos, radix astragali, rhizoma polygonati, rhizoma curcumae, rhizoma sparganii, rhizoma corydalis, cnidii fructus, processed rhizoma arisaematis and galla chinensis. The compound Chinese patent medicine has the efficacy of clearing away heat and toxic materials, resolving dampness, eliminating phlegm, strengthening the body resistanceto eliminate pathogenic factors and harmonizing five internal organs, can be used for treating the morbidity initial stage, the clinical treatment phase and the disease recovery phase of the COVID-19,and also can be used for preventing the COVID-19. According to a screening result of a cell level, calculation is carried out to obtain that the CC50 of the compound Chinese patent medicine is 177.83[mu] g / mL, the EC50 of the compound Chinese patent medicine is 89.13 [mu] g / mL, and a selection index SI is 1.995 so as to indicate that the compound Chinese patent medicine has an inhibition effect on the SARS-CoV-2. An acute and long-term drug administration toxicology experiment result indicates that the compound Chinese patent medicine is safe under a clinical recommended dose. Therefore, the compound Chinese patent medicine can be applied to the treatment and the prevention of the COVID-19, has a good treatment effect and does not have toxic or side effect.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of a compound Chinese patent medicine in the treatment of novel coronavirus-infected pneumonia COVID-19. Background technique [0002] Novel coronavirus-infected pneumonia (COVID-19) refers to pneumonia caused by a novel coronavirus (SARS-CoV-2) infection. The novel coronavirus (SARS-CoV-2) belongs to the genus β coronavirus, has an envelope, and the particles are round or oval, often pleomorphic, with a diameter of 60-140nm. When adopting chemical medicine to carry out antiviral treatment, the toxic side effect that produces is bigger. The new coronary pneumonia caused by the new coronavirus (SARS-CoV-2) infection belongs to the syndrome of plague, dampness, heat, and epidemic toxins accumulated in the lungs of the qi in traditional Chinese medicine, and both dampness, heat, poison and evil are emphasized, so it can be treated from the perspective of traditiona...

AI Technical Summary

Problems solved by technology

The effective rates of enzyme-lowering curative effect of Qiankunning tablet group and Fufang Yigan pill group were 83.48% and 77.16% in ITT population, and 87.62% and 83.84% in PP population; The curative effect and effective rate were slightly higher than those of the control group, but the difference between the two groups was not statistically significant

Images